Kantarjian et al53 assessed the efficacy and protection of dasatinib, as compared with imatinib, for the very first-line treatment of CML-CP. Five hundred and nineteen patients with recently diagnosed CML-CP have been randomly assigned to get dasatinib in a dose of one hundred mg after day-to-day (259 individuals) or imatinib https://menachemu742kpu5.blogadvize.com/profile